Microbiome therapeutics — Advances and challenges

Advanced Drug Delivery Reviews

Volumn 105, Issue , 2016, Pages 44-54

  Mimee, Mark ^a,b   Citorik, Robert J ^a,b   Lu, Timothy K ^a,b,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c USA   (United States)

Author keywords

Bacteriophage; Host bacteria interactions; Microbial ecology; Microbiome; Synthetic biology

Indexed keywords

BACTERIA; BACTERIOPHAGES; ECOLOGY;

CELLULAR THERAPY; HUMAN BODIES; HUMAN MICROBIOTA; MICROBIAL COMMUNITIES; MICROBIAL ECOLOGY; MICROBIOME; SYNTHETIC BIOLOGY; SYNTHETIC GENE CIRCUITS;

GENE THERAPY;

ANTIBIOTIC AGENT; BACTERIOCIN; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

BACTERIOPHAGE; BIFIDOBACTERIUM; BIOSENSOR; BRAIN; CLOSTRIDIUM DIFFICILE INFECTION; DRUG SYNTHESIS; ESCHERICHIA COLI; GENETIC ENGINEERING; GENETIC STABILITY; HOST RESISTANCE; HUMAN; IMMUNITY; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; LACTOBACILLUS; METABOLISM; MICROBIAL COLONIZATION; MICROBIAL COMMUNITY; MICROBIAL CONSORTIUM; MICROBIOME; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYNTHETIC BIOLOGY; ANIMAL; BIOENGINEERING; MICROFLORA;

ANIMALS; ANTI-INFECTIVE AGENTS; BIOENGINEERING; HUMANS; MICROBIOTA; PROBIOTICS;

EID: 84966560351     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.032     Document Type: Review

References (172)

1. [1] Human Microbiome Project Consortium, Structure, function and diversity of the healthy human microbiome. Nature 486 (2012), 207–214, 10.1038/nature11234.
2. [2] Dominguez-Bello, M.G., Costello, E.K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N., et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. 107 (2010), 11971–11975, 10.1073/pnas.1002601107.
3. [3] Bergstrom, A., Skov, T.H., Bahl, M.I., Roager, H.M., Christensen, L.B., Ejlerskov, K.T., et al. Establishment of intestinal microbiota during early life: a longitudinal, explorative study of a large cohort of Danish infants. Appl. Environ. Microbiol. 80 (2014), 2889–2900, 10.1128/AEM.00342-14.
4. [4] Cho, I., Yamanishi, S., Cox, L., Methé, B.a., Zavadil, J., Li, K., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488 (2012), 621–626, 10.1038/nature11400.
5. [5] Faith, J.J., Guruge, J.L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A.L., et al. The long-term stability of the human gut microbiota. Science, 341, 2013, 1237439, 10.1126/science.1237439.
6. [6] Franzosa, E.A., Huang, K., Meadow, J.F., Gevers, D., Lemon, K.P., Bohannan, B.J.M., et al. Identifying personal microbiomes using metagenomic codes. Proc. Natl. Acad. Sci. 112 (2015), E2930–E2938, 10.1073/pnas.1423854112.
7. [7] Maurice, C.F., Haiser, H.J., Turnbaugh, P.J., Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152 (2013), 39–50, 10.1016/j.cell.2012.10.052.
8. [8] Morgan, X.C., Tickle, T.L., Sokol, H., Gevers, D., Devaney, K.L., Ward, D.V., et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol., 13, 2012, R79, 10.1186/gb-2012-13-9-r79.
9. [9] Voreades, N., Kozil, A., Weir, T.L., Diet and the development of the human intestinal microbiome. Front. Microbiol. 5 (2014), 1–9, 10.3389/fmicb.2014.00494.
10. [10] Lozupone, C.a., Stombaugh, J.I., Gordon, J.I., Jansson, J.K., Knight, R., Diversity, stability and resilience of the human gut microbiota. Nature 489 (2012), 220–230, 10.1038/nature11550.
11. [11] David, L.a., Maurice, C.F., Carmody, R.N., Gootenberg, D.B., Button, J.E., Wolfe, B.E., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505 (2014), 559–563, 10.1038/nature12820.
12. [12] Zhang, C., Zhang, M., Pang, X., Zhao, Y., Wang, L., Zhao, L., Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. ISME J. 6 (2012), 1848–1857, 10.1038/ismej.2012.27.
13. [13] Carmody, R.N., Gerber, G.K., Luevano, J.M., Gatti, D.M., Somes, L., Svenson, K.L., et al. Diet dominates host genotype in shaping the murine gut microbiota. Cell Host Microbe 17 (2015), 72–84, 10.1016/j.chom.2014.11.010.
14. [14] Dey, N., Wagner, V.E., Blanton, L.V., Haque, R., Ahmed, T., Gordon, J.I., et al. Regulators of gut motility revealed by a gnotobiotic model of diet-microbiome interactions related to article regulators of gut motility revealed by a gnotobiotic model of diet-microbiome interactions related to travel. Cell 163 (2015), 95–107, 10.1016/j.cell.2015.08.059.
15. [15] Goodrich, J.K., Waters, J.L., Poole, A.C., Sutter, J.L., Koren, O., Blekhman, R., et al. Human genetics shape the gut microbiome. Cell 159 (2014), 789–799, 10.1016/j.cell.2014.09.053.
16. [16] Ley, R.E., Bäckhed, F., Turnbaugh, P., Lozupone, C.a., Knight, R.D., Gordon, J.I., Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. 102 (2005), 11070–11075, 10.1073/pnas.0504978102.
17. [17] Turnbaugh, P.J., Ley, R.E., Mahowald, M.a., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031, 10.1038/nature05414.
18. [18] Ridaura, V.K., Faith, J.J., Rey, F.E., Cheng, J., Duncan, A.E., Kau, A.L., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 341, 2013, 1241214, 10.1126/science.1241214.
19. [19] Smith, M.I., Yatsunenko, T., Manary, M.J., Trehan, I., Mkakosya, R., Cheng, J., et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 339 (2013), 548–554, 10.1126/science.1229000.
20. [20] Canfora, E.E., Jocken, J.W., Blaak, E.E., Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11 (2015), 577–591, 10.1038/nrendo.2015.128.
21. [21] Fischbach, M.a., Sonnenburg, J.L., Eating for two: how metabolism establishes interspecies interactions in the gut. Cell Host Microbe 10 (2011), 336–347, 10.1016/j.chom.2011.10.002.
22. [22] Krishnan, S., Alden, N., Lee, K., Pathways and functions of gut microbiota metabolism impacting host physiology. Curr. Opin. Biotechnol. 36 (2015), 137–145, 10.1016/j.copbio.2015.08.015.
23. [23] Donohoe, D.R., Garge, N., Zhang, X., Sun, W., O'Connell, T.M., Bunger, M.K., et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian Colon. Cell Metab. 13 (2011), 517–526, 10.1016/j.cmet.2011.02.018.
24. [24] Blouin, J.-M., Penot, G., Collinet, M., Nacfer, M., Forest, C., Laurent-Puig, P., et al. Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. Int. J. Cancer 128 (2011), 2591–2601, 10.1002/ijc.25599.
25. [25] Kelly, C.J., Zheng, L., Campbell, E.L., Saeedi, B., Scholz, C.C., Bayless, A.J., et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 17 (2015), 662–671, 10.1016/j.chom.2015.03.005.
26. [26] Davie, J.R., Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133 (2003), 2485S–2493S ( http://www.ncbi.nlm.nih.gov/pubmed/12840228).
27. [27] Brown, A.J., Goldsworthy, S.M., Barnes, A.A., Eilert, M.M., Tcheang, L., Daniels, D., et al. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278 (2003), 11312–11319, 10.1074/jbc.M211609200.
28. [28] Samuel, B.S., Shaito, A., Motoike, T., Rey, F.E., Backhed, F., Manchester, J.K., et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl. Acad. Sci. 105 (2008), 16767–16772, 10.1073/pnas.0808567105.
29. [29] Soret, R., Chevalier, J., De Coppet, P., Poupeau, G., Derkinderen, P., Segain, J.P., et al. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology 138 (2010), 1772–1782, 10.1053/j.gastro.2010.01.053.
30. [30] De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156 (2014), 84–96, 10.1016/j.cell.2013.12.016.
31. [31] Tolhurst, G., Heffron, H., Lam, Y.S., Parker, H.E., Habib, A.M., Diakogiannaki, E., et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61 (2012), 364–371, 10.2337/db11-1019.
32. [32] Degnan, P.H., Taga, M.E., Goodman, A.L., Vitamin B12 as a modulator of gut microbial ecology. Cell Metab. 20 (2014), 769–778, 10.1016/j.cmet.2014.10.002.
33. [33] Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 (2011), 57–63, 10.1038/nature09922.
34. [34] Koeth, R.A., Levison, B.S., Culley, M.K., Buffa, J.A., Wang, Z., Gregory, J.C., et al. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 20 (2014), 799–812, 10.1016/j.cmet.2014.10.006.
35. [35] Gregory, J.C., Buffa, J.A., Org, E., Wang, Z., Levison, B.S., Zhu, W., et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J. Biol. Chem. 290 (2015), 5647–5660, 10.1074/jbc.M114.618249.
36. [36] Wang, Z., Roberts, A.B., Buffa, J.A., Levison, B.S., Zhu, W., Org, E., et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163 (2015), 1585–1595, 10.1016/j.cell.2015.11.055.
37. [37] Dobkin, J.F., Saha, J.R., Butler, V.P., Neu, H.C., Lindenbaum, J., Digoxin-inactivating bacteria: identification in human gut flora. Science 220 (1983), 325–327 ( http://www.ncbi.nlm.nih.gov/pubmed/6836275).
38. [38] Haiser, H.J., Gootenberg, D.B., Chatman, K., Sirasani, G., Balskus, E.P., Turnbaugh, P.J., Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341 (2013), 295–298, 10.1126/science.1235872.
39. [39] Wallace, B.D., Wang, H., Lane, K.T., Scott, J.E., Orans, J., Koo, J.S., et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330 (2010), 831–835, 10.1126/science.1191175.
40. [40] Belkaid, Y., Hand, T.W., Role of the microbiota in immunity and inflammation. Cell 157 (2014), 121–141, 10.1016/j.cell.2014.03.011.
41. [41] Kabat, A.M., Srinivasan, N., Maloy, K.J., Modulation of immune development and function by intestinal microbiota. Trends Immunol. 35 (2014), 507–517, 10.1016/j.it.2014.07.010.
42. [42] Round, J.L., Mazmanian, S.K., The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9 (2009), 313–323, 10.1038/nri2614.
43. [43] Wlodarska, M., Kostic, A.D., Xavier, R.J., An integrative view of microbiome-host interactions in inflammatory bowel diseases. Cell Host Microbe 17 (2015), 577–591, 10.1016/j.chom.2015.04.008.
44. [44] Vujkovic-Cvijin, I., Dunham, R.M., Iwai, S., Maher, M.C., Albright, R.G., Broadhurst, M.J., et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci. Transl. Med., 5, 2013, 10.1126/scitranslmed.3006438 (193ra91).
45. [45] Shulzhenko, N., Morgun, A., Hsiao, W., Battle, M., Yao, M., Gavrilova, O., et al. Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat. Med. 17 (2011), 1585–1593, 10.1038/nm.2505.
46. [46] Garrett, W.S., Gallini, C.A., Yatsunenko, T., Michaud, M., Dubois, A., Delaney, M.L., et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8 (2010), 292–300, 10.1016/j.chom.2010.08.004.
47. [47] Haberman, Y., Tickle, T.L., Dexheimer, P.J., Kim, M., Tang, D., Karns, R., et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J. Clin. Invest. 124 (2014), 3617–3633, 10.1172/JCI75436.
48. [48] Mazmanian, S.K., Round, J.L., Kasper, D.L., A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453 (2008), 620–625, 10.1038/nature07008.
49. [49] Round, J.L., Mazmanian, S.K., Inducible Foxp3 + regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl. Acad. Sci. 107 (2010), 12204–12209, 10.1073/pnas.0909122107.
50. [50] Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331 (2011), 337–341, 10.1126/science.1198469.
51. [51] Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.a., Nakato, G., Takahashi, D., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504 (2013), 446–450, 10.1038/nature12721.
52. [52] Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504 (2013), 451–455, 10.1038/nature12726.
53. [53] Yang, Y., Torchinsky, M.B., Gobert, M., Xiong, H., Xu, M., Linehan, J.L., et al. Focused specificity of intestinal Th17 cells towards commensal bacterial antigens. Nature 510 (2014), 152–156, 10.1038/nature13279.
54. [54] Ivanov, I.I., Atarashi, K., Manel, N., Brodie, E.L., Shima, T., Karaoz, U., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139 (2009), 485–498, 10.1016/j.cell.2009.09.033.
55. [55] Arrieta, M.-C., Stiemsma, L.T., Dimitriu, P.A., Thorson, L., Russell, S., Yurist-Doutsch, S., et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci. Transl. Med., 7, 2015, 10.1126/scitranslmed.aab2271 (307ra152–307ra152).
56. [56] Stefka, A.T., Feehley, T., Tripathi, P., Qiu, J., McCoy, K., Mazmanian, S.K., et al. Commensal bacteria protect against food allergen sensitization. Proc. Natl. Acad. Sci. 111 (2014), 13145–13150, 10.1073/pnas.1412008111.
57. [57] Sassone-Corsi, M., Raffatellu, M., No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. J. Immunol. 194 (2015), 4081–4087, 10.4049/jimmunol.1403169.
58. [58] Buffie, C.G., Pamer, E.G., Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 13 (2013), 790–801, 10.1038/nri3535.
59. [59] Rupnik, M., Wilcox, M.H., Gerding, D.N., Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7 (2009), 526–536, 10.1038/nrmicro2164.
60. [60] Deriu, E., Liu, J.Z., Pezeshki, M., Edwards, R.A., Ochoa, R.J., Contreras, H., et al. Probiotic bacteria reduce Salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe. 14 (2013), 26–37, 10.1016/j.chom.2013.06.007.
61. [61] Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 (2014), 205–220, 10.1038/nature13828.
62. [62] Russell, A.B., Wexler, A.G., Harding, B.N., Whitney, J.C., Bohn, A.J., Goo, Y.A., et al. A type VI secretion-related pathway in Bacteroidetes mediates interbacterial antagonism. Cell Host Microbe, 2014, 1–10, 10.1016/j.chom.2014.07.007.
63. [63] Ng, K.M., Ferreyra, J.A., Higginbottom, S.K., Lynch, J.B., Kashyap, P.C., Gopinath, S., et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 502 (2013), 96–99, 10.1038/nature12503.
64. [64] Ferreyra, J.A., Wu, K.J., Hryckowian, A.J., Bouley, D.M., Weimer, B.C., Sonnenburg, J.L., Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe. 16 (2014), 770–777, 10.1016/j.chom.2014.11.003.
65. [65] Lyte, M., Cryan, J.F., Microbial Endocrinology: The Microbiota–Gut–Brain Axis in Health and Disease. 2014, Springer.
66. [66] Sharon, G., Garg, N., Debelius, J., Knight, R., Dorrestein, P.C., Mazmanian, S.K., Perspective specialized metabolites from the microbiome in health and disease. Cell Metab. 20 (2014), 719–730, 10.1016/j.cmet.2014.10.016.
67. [67] Sampson, T.R., Mazmanian, S.K., Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 17 (2015), 565–576, 10.1016/j.chom.2015.04.011.
68. [68] Yano, J.M., Yu, K., Donaldson, G.P., Shastri, G.G., Ann, P., Ma, L., et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161 (2015), 264–276, 10.1016/j.cell.2015.02.047.
69. [69] Williams, B.B., Van Benschoten, A.H., Cimermancic, P., Donia, M.S., Zimmermann, M., Taketani, M., et al. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe, 1–9, 2014, 10.1016/j.chom.2014.09.001.
70. [70] Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X.-N., et al. Postnatal microbial colonization programs the hypothalamic–pituitary–adrenal system for stress response in mice. J. Physiol. 558 (2004), 263–275, 10.1113/jphysiol.2004.063388.
71. [71] Hsiao, E.Y., McBride, S.W., Hsien, S., Sharon, G., Hyde, E.R., McCue, T., et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155 (2013), 1451–1463, 10.1016/j.cell.2013.11.024.
72. [72] Derrien, M., van Hylckama Vlieg, J.E.T., Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol. 23 (2015), 354–366, 10.1016/j.tim.2015.03.002.
73. [73] Marchesi, J.R., Adams, D.H., Fava, F., Hermes, G.D.a., Hirschfield, G.M., Hold, G., et al. The gut microbiota and host health: a new clinical frontier. Gut, 2015, 1–10, 10.1136/gutjnl-2015-309990.
74. [74] Frei, R., Akdis, M., O'Mahony, L., Prebiotics, probiotics, synbiotics, and the immune system. Curr. Opin. Gastroenterol. 31 (2015), 153–158, 10.1097/MOG.0000000000000151.
75. [75] de LeBlanc, A.d.M., Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications. World J. Gastroenterol., 20, 2014, 16518, 10.3748/wjg.v20.i44.16518.
76. [76] Varankovich, N.V., Nickerson, M.T., Korber, D.R., Probiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseases. Front. Microbiol. 6 (2015), 1–14, 10.3389/fmicb.2015.00685.
77. [77] Cuello-Garcia, C.a., Brożek, J.L., Fiocchi, A., Pawankar, R., Yepes-Nuñez, J.J., Terracciano, L., et al. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. J. Allergy Clin. Immunol., 2015, 1–10, 10.1016/j.jaci.2015.04.031.
78. [78] Ritchie, M.L., Romanuk, T.N., A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE, 7, 2012, e34938, 10.1371/journal.pone.0034938.
79. [79] Zuccotti, G., Meneghin, F., Aceti, A., Barone, G., Callegari, M.L., Di Mauro, A., et al. Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis. Allergy, 70, 2015, 10.1111/all.12700 (n/a–n/a).
80. [80] Fujiya, M., Ueno, N., Kohgo, Y., Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials. Clin. J. Gastroenterol. 7 (2014), 1–13, 10.1007/s12328-013-0440-8.
81. [81] Duan, F., March, J.C., Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc. Natl. Acad. Sci. 107 (2010), 11260–11264, 10.1073/pnas.1001294107.
82. [82] Lagenaur, L.A., Sanders-Beer, B.E., Brichacek, B., Pal, R., Liu, X., Liu, Y., et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 4 (2011), 648–657, 10.1038/mi.2011.30.
83. [83] Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289 (2000), 1352–1355, 10.1126/science.289.5483.1352.
84. [84] Braat, H., Rottiers, P., Hommes, D.W., Huyghebaert, N., Remaut, E., Remon, J., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4 (2006), 754–759, 10.1016/j.cgh.2006.03.028.
85. [85] Takiishi, T., Korf, H., Van Belle, T.L., Robert, S., Grieco, F.a., Caluwaerts, S., et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J. Clin. Invest. 122 (2012), 1717–1725, 10.1172/JCI60530.
86. [86] Robert, S., Gysemans, C., Takiishi, T., Korf, H., Spagnuolo, I., Sebastiani, G., et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes 63 (2014), 2876–2887, 10.2337/db13-1236.
87. [87] Hamady, Z.Z.R., Scott, N., Farrar, M.D., Wadhwa, M., Dilger, P., Whitehead, T.R., et al. Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-β1 under the control of dietary xylan. Inflamm. Bowel Dis. 17 (2011), 1925–1935, 10.1002/ibd.21565.
88. [88] Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3 (2010), 49–56, 10.1038/mi.2009.116.
89. [89] Hamady, Z.Z.R., Scott, N., Farrar, M.D., Lodge, J.P.A., Holland, K.T., Whitehead, T., et al. Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut 59 (2010), 461–469, 10.1136/gut.2008.176131.
90. [90] Motta, J.-P., Bermudez-Humaran, L.G., Deraison, C., Martin, L., Rolland, C., Rousset, P., et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci. Transl. Med., 4, 2012, 10.1126/scitranslmed.3004212 (158ra144–158ra144).
91. [91] Caluwaerts, S., Vandenbroucke, K., Steidler, L., Neirynck, S., Vanhoenacker, P., Corveleyn, S., et al. AG013, a mouth rinse formulation of Lactococcus lactis secreting human trefoil factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 46 (2010), 564–570, 10.1016/j.oraloncology.2010.04.008.
92. [92] Limaye, S.A., Haddad, R.I., Cilli, F., Sonis, S.T., Colevas, a.D., Brennan, M.T., et al. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119 (2013), 4268–4276, 10.1002/cncr.28365.
93. [93] Chen, Z., Guo, L., Zhang, Y., Walzem, R.L., Pendergast, J.S., Printz, R.L., et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J. Clin. Invest. 119 (2014), 1–16, 10.1172/JCI72517.
94. [94] Duan, F.F., Liu, J.H., March, J.C., Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 64 (2015), 1794–1803, 10.2337/db14-0635.
95. [95] Kassam, Z., Lee, C.H., Yuan, Y., Hunt, R.H., Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am. J. Gastroenterol. 108 (2013), 500–508, 10.1038/ajg.2013.59.
96. [96] van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368 (2013), 407–415, 10.1056/NEJMoa1205037.
97. [97] Smith, M.B., Kelly, C., Alm, E.J., How to regulate faecal transplants. Nature 506 (2014), 290–291, 10.1038/506290a.
98. [98] Petrof, E., Gloor, G., Vanner, S., Weese, S., Carter, D., Daigneault, M., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: “RePOOPulating” the gut. Microbiome, 1, 2013, 3 http://www.microbiomejournal.com/content/1/1/3.
99. [99] Ratner, M., Microbial cocktails join fecal transplants in IBD treatment trials. Nat. Biotechnol. 33 (2015), 787–788, 10.1038/nbt0815-787.
100. [100] Moayyedi, P., Surette, M.G., Kim, P.T., Libertucci, J., Wolfe, M., Onischi, C., et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149 (2015), 102–109, e6, 10.1053/j.gastro.2015.04.001.
101. [101] Ianiro, G., Bibbò, S., Scaldaferri, F., Gasbarrini, A., Cammarota, G., Fecal microbiota transplantation in inflammatory bowel disease. Medicine (Baltimore), 93, 2014, e97, 10.1097/MD.0000000000000097.
102. [102] Shen, T.D., Albenberg, L., Bittinger, K., Chehoud, C., Chen, Y., Judge, C.a., et al. Engineering the gut microbiota to treat hyperammonemia. J. Clin. Invest. 125 (2015), 2841–2850, 10.1172/JCI79214.
103. [103] Walsh, C.J., Guinane, C.M., Hill, C., Ross, R.P., O'Toole, P.W., Cotter, P.D., In silico identification of bacteriocin gene clusters in the gastrointestinal tract, based on the human microbiome project's reference genome database. BMC Microbiol., 15, 2015, 183, 10.1186/s12866-015-0515-4.
104. [104] Zheng, J., Gänzle, M.G., Lin, X.B., Ruan, L., Sun, M., Diversity and dynamics of bacteriocins from human microbiome. Environ. Microbiol. 17 (2015), 2133–2143, 10.1111/1462-2920.12662.
105. [105] Kommineni, S., Bretl, D.J., Lam, V., Chakraborty, R., Hayward, M., Simpson, P., et al. Bacteriocin production augments niche competition by enterococci in the mammalian gastrointestinal tract. Nature, 2015, 10.1038/nature15524.
106. [106] Corr, S.C., Li, Y., Riedel, C.U., O'Toole, P.W., Hill, C., Gahan, C.G.M., Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl. Acad. Sci. 104 (2007), 7617–7621, 10.1073/pnas.0700440104.
107. [107] Millette, M., Cornut, G., Dupont, C., Shareck, F., Archambault, D., Lacroix, M., Capacity of human nisin- and pediocin-producing lactic acid bacteria to reduce intestinal colonization by vancomycin-resistant enterococci. Appl. Environ. Microbiol. 74 (2008), 1997–2003, 10.1128/AEM.02150-07.
108. [108] Twort, F.W., An investigation on the nature of ultra-microscopic viruses. Lancet 186 (1915), 1241–1243, 10.1016/S0140-6736(01)20383–3.
109. [109] d'Herelle, F., Sur un microbe invisible antagoniste des bacilles dysentériques. CR Acad. Sci. Paris 165 (1917), 373–375.
110. [110] Reardon, S., Phage therapy gets revitalized. Nature 510 (2014), 15–16, 10.1038/510015a.
111. [111] Kingwell, K., Bacteriophage therapies re-enter clinical trials. Nat. Rev. Drug Discov. 14 (2015), 515–516, 10.1038/nrd4695.
112. [112] Sulakvelidze, A., Alavidze, Z., Morris, J.G., Bacteriophage therapy. Antimicrob. Agents Chemother. 45 (2001), 649–659, 10.1128/AAC.45.3.649-659.2001.
113. [113] Weiss, M., Denou, E., Bruttin, A., Serra-Moreno, R., Dillmann, M.-L., Brüssow, H., In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli. Virology 393 (2009), 16–23, 10.1016/j.virol.2009.07.020.
114. [114] Maura, D., Morello, E., du Merle, L., Bomme, P., Le Bouguénec, C., Debarbieux, L., Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice. Environ. Microbiol. 14 (2012), 1844–1854, 10.1111/j.1462-2920.2011.02644.x.
115. [115] Mills, S., Shanahan, F., Stanton, C., Hill, C., Coffey, A., Ross, R.P., Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes 4 (2013), 4–16, 10.4161/gmic.22371.
116. [116] Reyes, A., Haynes, M., Hanson, N., Angly, F.E., Heath, A.C., Rohwer, F., et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 466 (2010), 334–338, 10.1038/nature09199.
117. [117] Minot, S., Sinha, R., Chen, J., Li, H., Keilbaugh, S.A., Wu, G.D., et al. The human gut virome: inter-individual variation and dynamic response to diet. Genome Res. 21 (2011), 1616–1625, 10.1101/gr.122705.111.
118. [118] Norman, J.M., Handley, S.A., Baldridge, M.T., Droit, L., Liu, C.Y., Keller, B.C., et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160 (2015), 447–460, 10.1016/j.cell.2015.01.002.
119. [119] Modi, S.R., Lee, H.H., Spina, C.S., Collins, J.J., Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. Nature 499 (2013), 219–222, 10.1038/nature12212.
120. [120] Reyes, A., Wu, M., McNulty, N.P., Rohwer, F.L., Gordon, J.I., Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut. Proc. Natl. Acad. Sci. 110 (2013), 20236–20241, 10.1073/pnas.1319470110.
121. [121] Barr, J.J., Auro, R., Furlan, M., Whiteson, K.L., Erb, M.L., Pogliano, J., et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc. Natl. Acad. Sci. 110 (2013), 10771–10776, 10.1073/pnas.1305923110.
122. [122] Ando, H., Lemire, S., Pires, D.P., Lu, T.K., Engineering modular viral scaffolds for targeted bacterial population editing. Cell Syst. 1 (2015), 187–196, 10.1016/j.cels.2015.08.013.
123. [123] Lu, T.K., Collins, J.J., Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. 104 (2007), 11197–11202 ( http://www.pnas.org/content/104/27/11197.abstract).
124. [124] Lu, T.K., Collins, J.J., Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. 106 (2009), 4629–4634 ( http://www.pnas.org/content/106/12/4629.abstract).
125. [125] Edgar, R., Friedman, N., Molshanski-Mor, S., Qimron, U., Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl. Environ. Microbiol. 78 (2012), 744–751, 10.1128/AEM.05741-11.
126. [126] Westwater, C., Kasman, L.M., Schofield, D.A., Werner, P.A., Dolan, J.W., Schmidt, M.G., et al. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 47 (2003), 1301–1307, 10.1128/AAC.47.4.1301.
127. [127] Hagens, S., Habel, A., von Ahsen, U., von Gabain, A., Bläsi, U., Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother. 48 (2004), 3817–3822, 10.1128/AAC.48.10.3817-3822.2004.
128. [128] Krom, R.J., Bhargava, P., Lobritz, M.a., Collins, J.J., Engineered phagemids for nonlytic, targeted antibacterial therapies. Nano Lett. 15 (2015), 4808–4813, 10.1021/acs.nanolett.5b01943.
129. [129] Bikard, D., Euler, C.W., Jiang, W., Nussenzweig, P.M., Goldberg, G.W., Duportet, X., et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol., 2014, 1–6, 10.1038/nbt.3043.
130. [130] Citorik, R.J., Mimee, M., Lu, T.K., Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol. 32 (2014), 1141–1145, 10.1038/nbt.3011.
131. [131] Kiro, R., Shitrit, D., Qimron, U., Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system. RNA Biol. 11 (2014), 42–44, 10.4161/rna.27766.
132. [132] Gibson, D.G., Young, L., Chuang, R.-Y., Venter, J.C., Hutchison, C.A., Smith, H.O., Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6 (2009), 343–345, 10.1038/nmeth.1318.
133. [133] Joeres-Nguyen-Xuan, T.H., Boehm, S.K., Joeres, L., Schulze, J., Kruis, W., Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. Inflamm. Bowel Dis. 16 (2010), 256–262, 10.1002/ibd.21042.
134. [134] Seedorf, H., Griffin, N.W., Ridaura, V.K., Reyes, A., Cheng, J., Rey, F.E., et al. Bacteria from diverse habitats colonize and compete in the mouse gut. Cell 159 (2014), 253–266, 10.1016/j.cell.2014.09.008.
135. [135] Wu, M., McNulty, N.P., Rodionov, D.a., Khoroshkin, M.S., Griffin, N.W., Cheng, J., et al. Genetic determinants of in vivo fitness and diet responsiveness in multiple human gut Bacteroides. Science, 350, 2015, 10.1126/science.aac5992 (aac5992–aac5992).
136. [136] Sonnenburg, E.D., Zheng, H., Joglekar, P., Higginbottom, S.K., Firbank, S.J., Bolam, D.N., et al. Specificity of polysaccharide use in intestinal Bacteroides species determines diet-induced microbiota alterations. Cell 141 (2010), 1241–1252, 10.1016/j.cell.2010.05.005.
137. [137] Lee, S.M., Donaldson, G.P., Mikulski, Z., Boyajian, S., Ley, K., Mazmanian, S.K., Bacterial colonization factors control specificity and stability of the gut microbiota. Nature 501 (2013), 426–429, 10.1038/nature12447.
138. [138] Goodman, A.L., McNulty, N.P., Zhao, Y., Leip, D., Mitra, R.D., Lozupone, C.a., et al. Identifying genetic determinants needed to establish a human gut symbiont in its habitat. Cell Host Microbe. 6 (2009), 279–289, 10.1016/j.chom.2009.08.003.
139. [139] Cullen, T.W., Schofield, W.B., Barry, N.A., Putnam, E.E., Rundell, E.A., Trent, M.S., et al. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science 347 (2015), 170–175, 10.1126/science.1260580.
140. [140] Levy, R., Borenstein, E., Metabolic modeling of species interaction in the human microbiome elucidates community-level assembly rules. Proc. Natl. Acad. Sci. 110 (2013), 12804–12809, 10.1073/pnas.1300926110.
141. [141] Greenblum, S., Chiu, H.-C., Levy, R., Carr, R., Borenstein, E., Towards a predictive systems-level model of the human microbiome: progress, challenges, and opportunities. Curr. Opin. Biotechnol. 24 (2013), 810–820, 10.1016/j.copbio.2013.04.001.
142. [142] Mimee, M., Tucker, A.C., Voigt, C.A., Lu, T.K., Programming a human commensal bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota. Cell Syst., 2015, 1–10, 10.1016/j.cels.2015.06.001.
143. [143] Donaldson, G.P., Lee, S.M., Mazmanian, S.K., Gut biogeography of the bacterial microbiota. Nat. Rev. Microbiol. 14 (2015), 20–32, 10.1038/nrmicro3552.
144. [144] Li, H., Limenitakis, J.P., Fuhrer, T., Geuking, M.B., Lawson, M.a., Wyss, M., et al. The outer mucus layer hosts a distinct intestinal microbial niche. Nat. Commun., 2015, 10.1038/ncomms9292.
145. [145] Nava, G.M., Friedrichsen, H.J., Stappenbeck, T.S., Spatial organization of intestinal microbiota in the mouse ascending colon. ISME J. 5 (2011), 627–638, 10.1038/ismej.2010.161.
146. [146] Earle, K.A., Billings, G., Sigal, M., Lichtman, J.S., Hansson, G.C., Elias, J.E., et al. Quantitative imaging of gut microbiota spatial organization. Cell Host Microbe 18 (2015), 478–488, 10.1016/j.chom.2015.09.002.
147. [147] Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L.G., Gratadoux, J.-J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. 105 (2008), 16731–16736, 10.1073/pnas.0804812105.
148. [148] Gevers, D., Kugathasan, S., Denson, L.A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., et al. The treatment-naïve microbiome in new-onset Crohn's disease. Cell Host Microbe 15 (2014), 382–392, 10.1016/j.chom.2014.02.005.
149. [149] Siuti, P., Yazbek, J., Lu, T.K., Synthetic circuits integrating logic and memory in living cells. Nat. Biotechnol. 31 (2013), 448–452, 10.1038/nbt.2510.
150. [150] Bonnet, J., Yin, P., Ortiz, M.E., Subsoontorn, P., Endy, D., Amplifying genetic logic gates. Science 340 (2013), 599–603, 10.1126/science.1232758.
151. [151] Farzadfard, F., Lu, T.K., Genomically encoded analog memory with precise in vivo DNA writing in living cell populations. Science, 346, 2014, 6211, 10.1126/science.1256272.
152. [152] Gardner, T.S., Cantor, C.R., Collins, J.J., Construction of a genetic toggle switch in Escherichia coli. Nature 403 (2000), 339–342, 10.1038/35002131.
153. [153] Kotula, J.W., Kerns, S.J., Shaket, L.a., Siraj, L., Collins, J.J., Way, J.C., et al. Programmable bacteria detect and record an environmental signal in the mammalian gut. Proc. Natl. Acad. Sci. 111 (2014), 4838–4843, 10.1073/pnas.1321321111.
154. [154] Danino, T., Prindle, A., Kwong, G.A., Skalak, M., Li, H., Allen, K., et al. Programmable probiotics for detection of cancer in urine. Sci. Transl. Med., 7, 2015, 10.1126/scitranslmed.aaa3519 (289ra84–289ra84).
155. [155] Ellefson, J.W., Meyer, A.J., Hughes, R.a., Cannon, J.R., Brodbelt, J.S., Ellington, A.D., Directed evolution of genetic parts and circuits by compartmentalized partnered replication. Nat. Biotechnol. 32 (2013), 97–101, 10.1038/nbt.2714.
156. [156] Esvelt, K.M., Carlson, J.C., Liu, D.R., A system for the continuous directed evolution of biomolecules. Nature 472 (2011), 499–503, 10.1038/nature09929.
157. [157] Shis, D.L., Hussain, F., Meinhardt, S., Swint-Kruse, L., Bennett, M.R., Modular, multi-input transcriptional logic gating with orthogonal LacI/GalR family chimeras. ACS Synth. Biol. 3 (2014), 645–651, 10.1021/sb500262f.
158. [158] Chan, C.T.Y., Lee, J.W., Cameron, D.E., Bashor, C.J., Collins, J.J., “Deadman” and “Passcode” microbial kill switches for bacterial containment. Nat. Chem. Biol., 1–7, 2015, 10.1038/nchembio.1979.
159. [159] Chou, H.H., Keasling, J.D., Programming adaptive control to evolve increased metabolite production. Nat. Commun., 4, 2013, 2595, 10.1038/ncomms3595.
160. [160] Auchtung, J.M., Robinson, C.D., Britton, R.A., Cultivation of stable, reproducible microbial communities from different fecal donors using minibioreactor arrays (MBRAs). Microbiome, 3, 2015, 42, 10.1186/s40168-015-0106-5.
161. [161] McDonald, J.A.K., Schroeter, K., Fuentes, S., Heikamp-deJong, I., Khursigara, C.M., de Vos, W.M., et al. Evaluation of microbial community reproducibility, stability and composition in a human distal gut chemostat model. J. Microbiol. Methods 95 (2013), 167–174, 10.1016/j.mimet.2013.08.008.
162. [162] Van den Abbeele, P., Belzer, C., Goossens, M., Kleerebezem, M., De Vos, W.M., Thas, O., et al. Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model. ISME J. 7 (2013), 949–961, 10.1038/ismej.2012.158.
163. [163] Lukovac, S., Belzer, C., Pellis, L., Keijser, B.J., de Vos, W.M., Montijn, R.C., et al. Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids. MBio, 5, 2014, 10.1128/mBio.01438–14 (e01438–14–e01438–14).
164. [164] Costello, C.M., Sorna, R.M., Goh, Y., Cengic, I., Jain, N.K., March, J.C., 3D intestinal scaffolds for evaluating the therapeutic potential of probiotics. Mol. Pharm., 2015, 2030–2039.
165. [165] Kim, H.J., Li, H., Collins, J.J., Ingber, D.E., Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc. Natl. Acad. Sci., 201522193, 2015, 10.1073/pnas.1522193112.
166. [166] Ceroni, F., Algar, R., Stan, G.-B., Ellis, T., Quantifying cellular capacity identifies gene expression designs with reduced burden. Nat. Methods 12 (2015), 415–418, 10.1038/nmeth.3339.
167. [167] Springman, R., Molineux, I.J., Duong, C., Bull, R.J., Bull, J.J., Evolutionary stability of a refactored phage genome. ACS Synth. Biol. 1 (2012), 425–430, 10.1021/sb300040v.
168. [168] Gladstone, E.G., Molineux, I.J., Bull, J.J., Evolutionary principles and synthetic biology: avoiding a molecular tragedy of the commons with an engineered phage. J. Biol. Eng., 6, 2012, 13, 10.1186/1754-1611-6-13.
169. [169] Smillie, C.S., Smith, M.B., Friedman, J., Cordero, O.X., David, L.A., Alm, E.J., Ecology drives a global network of gene exchange connecting the human microbiome. Nature 480 (2011), 241–244, 10.1038/nature10571.
170. [170] Wright, O., Delmans, M., Stan, G.-B., Ellis, T., GeneGuard: a modular plasmid system designed for biosafety. ACS Synth. Biol., 140513123533005, 2014, 10.1021/sb500234s.
171. [171] Caliando, B.J., Voigt, C.A., Targeted DNA degradation using a CRISPR device stably carried in the host genome. Nat. Commun., 6, 2015, 6989, 10.1038/ncomms7989.
172. [172] Steidler, L., Neirynck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B., et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21 (2003), 785–789, 10.1038/nbt840.